Table 1 Patient demographics and baseline characteristics.

Characteristic, n	Sorafenib (n = 476)	Lenvatinib (n = 478)
Age, years
<60	283	270
60–75	126	150
>75	67	58
Sex
Male	401	405
Female	75	73
Region^a
Western	157	157
Asia-Pacific	319	321
Macroscopic portal vein invasion (MPVI)
Yes	90	109
No	386	369
Extrahepatic spread (EHS)
Yes	295	291
No	181	187
MPVI, EHS, or both^a
Yes	336	329
No	140	149
ECOG Performance status^a
0	301	304
1+	175	174
Bodyweight group, kg^a
<60	146	153
≥60	330	325
Alpha fetoprotein, ng/ml
<200	286	255
≥200	187	222
Missing	3	1
Child-Pugh score
5	357	368
6+	119	110
Number of disease sites
1	207	207
2	183	167
≥3	86	103
Etiology
HBV	228	251
HCV	126	91
Alcohol	21	36
Other	32	38
Unknown	69	62
Underlying cirrhosis
Yes	231	243
No	245	235
BCLC Staging
Stage B	92	104
Stage C	384	374
Prior procedure
Yes	344	327
No	132	151
Liver disease site
Not involved	46	37
Involved	430	441
Lung disease site
Not involved	332	315
Involved	144	163
Bone disease site
Not involved	433	427
Involved	43	51
Lymph node disease site
Not involved	335	351
Involved	141	127
Other disease site
Not Involved	379	396
Involved	97	82
Post-treatment therapy^b,c
Yes	243	206
No	233	272
Post-treatment procedure^b
Yes	112	99
No	364	379
Post-treatment medication^b
Yes	184	156
No	292	322

BCLC Barcelona Clinic Liver Cancer, ECOG PS Eastern Cooperative Oncology Group performance status, HBV hepatitis B virus, HCV hepatitis C virus.
^aStratification variables in the original Statistical Analysis Plan.
^bPost-trandomisation variables.
^cPost-treatment therapy = post-treatment procedure and/or post-treatment medication.

Quick links

Search